These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22904612)

  • 1. Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study.
    Cantini F; Niccoli L; Cassarà E; Kaloudi O; Nannini C
    Biologics; 2012; 6():201-6. PubMed ID: 22904612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations.
    Van den Bosch F; Kavanaugh A; Kron M; Kupper H; Mease PJ
    J Rheumatol; 2015 Jun; 42(6):952-9. PubMed ID: 25834212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up.
    Chen DY; Chen YM; Hsieh TY; Hung WT; Hsieh CW; Chen HH; Tang KT; Lan JL
    Rheumatology (Oxford); 2016 Jan; 55(1):143-8. PubMed ID: 26324949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
    Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
    Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
    Mease PJ; Smolen JS; Behrens F; Nash P; Liu Leage S; Li L; Tahir H; Gooderham M; Krishnan E; Liu-Seifert H; Emery P; Pillai SG; Helliwell PS;
    Ann Rheum Dis; 2020 Jan; 79(1):123-131. PubMed ID: 31563894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
    Alivernini S; Tolusso B; Petricca L; Bui L; Di Sante G; Peluso G; Benvenuto R; Fedele AL; Federico F; Ferraccioli G; Gremese E
    Ann Rheum Dis; 2017 Jul; 76(7):1228-1236. PubMed ID: 28119289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: A prospective multicentre study.
    Hoxha A; Calligaro A; Tonello M; Ramonda R; Carletto A; Paolazzi G; Bortolotti R; Del Ross T; Grava C; Boaretto M; Favaro M; Teghil V; Ruffatti A; Punzi L
    Joint Bone Spine; 2016 Mar; 83(2):167-71. PubMed ID: 26750762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of early adalimumab therapy in psoriatic arthritis patients from Reuma.pt - EARLY PsA.
    Santos H; Eusébio M; Borges J; Gonçalves D; Ávila-Ribeiro P; Faria DS; Lopes C; Rovisco J; Águeda A; Nero P; Valente P; Cravo AR; Santos MJ
    Acta Reumatol Port; 2017; 42(4):287-299. PubMed ID: 29342473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study.
    McInnes IB; Kato K; Magrey M; Merola JF; Kishimoto M; Haaland D; Chen L; Duan Y; Liu J; Lippe R; Wung P
    Rheumatol Ther; 2023 Feb; 10(1):275-292. PubMed ID: 36243812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of one-year treat-to-target strategy in early psoriatic arthritis: data of an open-label REMARCA study.
    Korotaeva TV; Loginova EY; Getiya TS; Nasonov EL
    Ter Arkh; 2018 May; 90(5):22-29. PubMed ID: 30701886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.
    Smolen JS; Mease P; Tahir H; Schulze-Koops H; de la Torre I; Li L; Hojnik M; Sapin C; Okada M; Caporali R; Gratacós J; Goupille P; Liu Leage S; Pillai S; Nash P
    Ann Rheum Dis; 2020 Oct; 79(10):1310-1319. PubMed ID: 32660977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Pasquetti P; Olivieri I; Salvarani C
    Rheumatology (Oxford); 2008 Jun; 47(6):872-6. PubMed ID: 18400836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs.
    Atteno M; Peluso R; Costa L; Padula S; Iervolino S; Caso F; Sanduzzi A; Lubrano E; Del Puente A; Scarpa R
    Clin Rheumatol; 2010 Apr; 29(4):399-403. PubMed ID: 20066450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study.
    Cantini F; Niccoli L; Cassarà E; Kaloudi O; Nannini C
    Biologics; 2013; 7():1-6. PubMed ID: 23319853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT).
    Mease PJ; Ory P; Sharp JT; Ritchlin CT; Van den Bosch F; Wellborne F; Birbara C; Thomson GT; Perdok RJ; Medich J; Wong RL; Gladman DD
    Ann Rheum Dis; 2009 May; 68(5):702-9. PubMed ID: 18684743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Criteria, frequency, and duration of clinical remission in psoriatic arthritis patients with peripheral involvement requiring second-line drugs.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Pasquetti P; Olivieri I; Salvarani C
    J Rheumatol Suppl; 2009 Aug; 83():78-80. PubMed ID: 19661551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.
    Favalli EG; Becciolini A; Carletto A; Conti F; Amato G; Fusaro E; Quartuccio L; Egan CG; Lo Monaco A; Benucci M; Salaffi F; Semeraro A; Parisi S; Ceccarelli F; Piazza I; Foti R
    Rheumatol Int; 2020 Feb; 40(2):263-272. PubMed ID: 31435754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.